EGFR and non-small cell lung carcinoma: Very recently, a phase III randomized trial named PALOMA-3 [51] evaluated the efficacy and safety of subcutaneous amivantamab compared to its intravenous formulation in combination with lazertinib in NSCLC, as third-line treatment of advanced EGFR-mutant NSCLC.